These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1412196)
1. Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Gresele P; Volpato R; Migliacci R; Vezza R; Boschetti E; Nenci GG Thromb Res; 1992 May; 66(2-3):259-64. PubMed ID: 1412196 [No Abstract] [Full Text] [Related]
2. A thromboxane synthetase inhibitor in Raynaud's phenomenon. Jones EW; Hawkey CJ Prostaglandins Leukot Med; 1983 Sep; 12(1):67-71. PubMed ID: 6356154 [TBL] [Abstract][Full Text] [Related]
3. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380 [TBL] [Abstract][Full Text] [Related]
4. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Ettinger WH; Wise RA; Schaffhauser D; Wigley FM Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986 [TBL] [Abstract][Full Text] [Related]
5. Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. Gresele P; Bounameaux H; Arnout J; Perez-Requejo JL; Deckmyn H; Vermylen J J Lab Clin Med; 1985 Nov; 106(5):534-41. PubMed ID: 2932514 [TBL] [Abstract][Full Text] [Related]
6. Role of digital artery adrenoceptors in Raynaud's disease. Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943 [TBL] [Abstract][Full Text] [Related]
7. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490 [TBL] [Abstract][Full Text] [Related]
8. Blood viscosity, finger systolic pressure and effect of dazoxiben treatment in primary vasospastic disease. Sandhagen B; Wegener T; Hägg A Ups J Med Sci; 1984; 89(3):213-9. PubMed ID: 6393521 [TBL] [Abstract][Full Text] [Related]
10. Reproducibility of cold provocation in patients with Raynaud's phenomenon. Wigley FM; Malamet R; Wise RA J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980 [TBL] [Abstract][Full Text] [Related]
11. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Belch JJ; Cormie J; Newman P; McLaren M; Barbenel J; Capell H; Leiberman P; Forbes CD; Prentice CR Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):113S-116S. PubMed ID: 6337601 [TBL] [Abstract][Full Text] [Related]
12. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Freedman RR; Moten M; Migály P; Mayes M Arthritis Rheum; 1993 May; 36(5):685-90. PubMed ID: 8387786 [TBL] [Abstract][Full Text] [Related]
13. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear. Umemura K; Asai Y; Uematsu T; Nakashima M Eur Arch Otorhinolaryngol; 1993; 250(6):342-4. PubMed ID: 8260145 [TBL] [Abstract][Full Text] [Related]
14. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon. Seibold JR; Terregino CA J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573 [TBL] [Abstract][Full Text] [Related]
15. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. Malamet R; Wise RA; Ettinger WH; Wigley FM Am J Med; 1985 Apr; 78(4):602-8. PubMed ID: 3157318 [TBL] [Abstract][Full Text] [Related]
16. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Dogné JM; de Leval X; Benoit P; Delarge J; Masereel B Am J Respir Med; 2002; 1(1):11-7. PubMed ID: 14720071 [TBL] [Abstract][Full Text] [Related]
17. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids. Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586 [TBL] [Abstract][Full Text] [Related]
18. Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats. Uriu K; Kaizu K; Hashimoto O; Komine N; Etoh S Kidney Int; 1994 Mar; 45(3):794-802. PubMed ID: 8196281 [TBL] [Abstract][Full Text] [Related]
19. Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon. Coppock JS; Hardman JM; Bacon PA; Woods KL; Kendall MJ Postgrad Med J; 1986 Jan; 62(723):15-8. PubMed ID: 3099273 [TBL] [Abstract][Full Text] [Related]
20. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]